Venetoclax Monotherapy for Relapsed/Refractory MM: Phase I Results

December 3-6, 2016; San Diego, California
Venetoclax was safe and tolerable in heavily pretreated patients with myeloma with an ORR of 40% in patients with t(11;14) translocation.
Format: Microsoft PowerPoint (.ppt)
File Size: 653 KB
Released: December 7, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Results of the MagnetisMM-1 phase I trial of subcutaneous elranatamab in patients with relapsed/refractory multiple myeloma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 14, 2021

Results from CASSIOPEIA part 2 of daratumumab maintenance therapy vs observation in newly diagnosed multiple myeloma from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.